Skip to main content

Table 1 Characteristics of the study population at T2, n(%), mean±SD

From: Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study

  aMCI
n=37
CU
n=72
Total
n=109
p-values
KLK8, pg/ml 911.6±619.8 783.1±633.0 826.7±628.7 0.24
Sex 23 (62.2)   69 (63.3) 0.86
Men 46 (63.9)  
Women 14 (37.8) 26 (36.1) 40 (36.7)  
Age, years 70.9±8.2 71.0±7.9 71.0±8.0 0.97
BMI, kg/m2 29.2±5.3 28.1±3.3 28.5±4.1 0.36
Years of education 14.0±2.4 14.7±2.4 14.5±2.4 0.20
Smoking status 16 (43.2)   49 (45.0) 0.82
Never 33 (45.8)  
Past 17 (45.9) 29 (40.3) 46 (42.2)  
Current 4 (10.8) 10 (13.9) 14 (12.8)  
Sports 18 (48.6)   49 (45.0) 0.58
No 31 (43.1)  
Yes 19 (51.4) 41 (56.9) 60 (55.0)  
APOE ε4 positive     0.01
No 17 (45.9) 52 (72.2) 69 (63.3)  
Yes 18 (48.6) 19 (26.4) 37 (33.9)  
Missing 2 (5.4) 1 (1.4) 3 (2.8)  
z score attention 9.5±4.2 11.3±1.8 10.7±2.9 0.02
z score executive function 8.7±3.7 11.3±1.8 10.4±2.9 <.01
z score verbal memory 5.9±1.1 11.2±2.3 9.4±3.2 <.01
z score visuoconstruction 10.3±2.7 11.2±1.9 10.9±2.3 0.11
Depressiona 6 (16.2) 0 6 (5.5) <.01
Missing 2 (5.4) 3 (4.2) 5  
Hypertension     0.82
No 27 (73.0) 54 (75.0) 81 (74.3)  
Yes 10 (27.0) 18 (25.0) 28 (25.7)  
Diabetes mellitus     0.54
No 32 (86.5) 59 (81.9) 91 (83.5)  
Yes 5 (13.5) 13 (18.1) 18 (16.5)  
Freezing duration, years 7.5±1.0 8.3±0.7 8.0±0.9 <.01
  1. T2 ten-year follow-up, SD standard deviation, aMCI amnestic mild cognitive impairement, CU cognitive unimpaired, KLK8 kallikrein 8, BMI body mass index, APOE ε4 Apolipoprotein E ε4
  2. a Elevated depressive symptoms (CES-D≥18)